U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 3:

Figure 3:. From: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial.

Ibuprofen intake and total pain calculated from the patient dairy.

P.R. Koninckx, et al. Hum Reprod. 2008 Sep;23(9):2017-2023.
2.
Figure 2:

Figure 2:. From: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial.

Induration, pelvic tenderness and total Biberoglu–Behrman score together with VAS scales as recorded at each visit and weekly by the patient in her diary, before treatment, during the 12 week treatment period (shaded area) and after surgery.
Baseline versus early treatment, NS; baseline versus late treatment, >0.003 for all except NS for VAS dysmenorrhea. Baseline and late treatment versus post-surgery: P < 0.001 for all. Infliximab: NS for all.

P.R. Koninckx, et al. Hum Reprod. 2008 Sep;23(9):2017-2023.
3.
Figure 1:

Figure 1:. From: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial.

Dysmenorrhea, deep dyspareunia and chronic pelvic pain, as assessed by the clinician (upper graphs) and by the patient in her diary, before treatment, during the 12 week treatment period (shaded area) and after surgery.
Baseline versus early treatment: NS, baseline versus late treatment: >0.003 for all. Baseline and late treatment versus post-surgery: P < 0.001 for all. Infliximab: NS for all.

P.R. Koninckx, et al. Hum Reprod. 2008 Sep;23(9):2017-2023.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center